Clear Search

Showing 7 result for “Kollmeier AP”.

September 2023

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589

Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.


April 2023

活動性乾癬性関節炎患者におけるTNF阻害薬使用歴の有無によるグセルクマブの有用性: フェーズ3 無作為化対照試験 DISCOVER-1

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523

TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.


March 2023

グセルクマブによる2年間の治療での臨床的有効性と画像的進行との関連: バイオ未治療で活動性乾癬性関節炎患者を対象としたフェーズ3無作為化二重盲検プラセボ対照試験結果

RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789

Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.


February 2023

活動性乾癬性関節炎患者の画像的進行抑制に対するguselkumabの効果: フェーズ3a 多施設共同無作為化二重盲検プラセボ対照試験、APEX試験のプロトコル

Trials. 2023 doi: 10.1186/s13063-022-06945-y

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.


TNFα阻害薬治療歴別のグセルクマブの安全性: 乾癬性関節炎患者を対象とした4試験の統合解析

J Rheumatol. 2023 jrheum

These results demonstrate that guselkumab was well tolerated in studies continuing for 1 to 2 years among patients with moderate-to-severe PsA regardless of TNFi experience and concomitant MTX use. The objective of this study was to assess pooled safety results from Phase 2/3 studies of guselkumab in TNFi-naïve and experienced PsA patients.


September 2022

バイオナイーブの活動性乾癬性関節炎患者におけるグセルクマブの健康状態に対する効果; フェーズ3無作為化プラセボ対照52週DISCOVER-2 試験

Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0

In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.


July 2022

活動性乾癬性関節炎患者においてguselkumab は複合 指標の各ドメインおよび全般的な有効性を示す

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375

This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.